Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Exploring Innovations in SPR & Combination Screening

Published: Tuesday, August 26, 2014
Last Updated: Wednesday, August 27, 2014
Bookmark and Share
Genedata customers will discuss innovations in high content imaging, high throughput screening, compound combination screening, and other related topics at User Group Meetings.

Scientists from AstraZeneca, Chugai Pharmaceutical, Sanford-Burnham Medical Research Institute, and UT Southwestern Medical Center will be among Genedata customers discussing innovations in high content imaging, high throughput screening, compound combination screening, and other related topics    

Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced the Genedata Screener® Global User Group Meetings will be held in Asia, Europe, and North America during September 2014. Screening experts from global pharmaceutical companies and leading research organizations will gather for annual User Group Meetings to share best practices, case studies, and upcoming challenges in all areas of screening. This year's sessions will also showcase enhancements and new functionality in the recently released Genedata Screener version 12, which includes data analysis capabilities for Surface Plasmon Resonance (SPR), Thermal Shift, as well as Combination and Panel Screens.
 
Most of the world's leading pharmaceutical companies, academic institutions, and contract research organizations rely on Genedata Screener as their single computational platform for all plate-based screening. Genedata Screener users from AstraZeneca, Chugai Pharmaceuticals, Sanford-Burnham Institute, and University of Texas Southwestern Medical Center will be among the speakers presenting their research work using Genedata Screener. Featured sessions will explore topics such as:  
 
•    application of high content imaging and stem cells within phenotypic drug discovery;
•    identification of novel natural products and synthetic molecules for treatment of lung cancer; and
•    best practices for applying Genedata Screener in a variety of screening environments.
 
"Screener User Group Meetings bring together many of the world's thought leaders in the application of screening technologies in pharmaceutical R&D," said Dr. Othmar Pfannes, CEO of Genedata. "We are proud to host these annual events, which provide forums in which scientists can share their experiences in advancing scientific progress with Genedata Screener -- the most comprehensive computational platform for screening worldwide."
 
Genedata Screener User Group Meetings are held regionally throughout the world so that customers can easily access and participate in these knowledge-sharing events. Meetings for 2014 will be held in: Tokyo, Japan (Sept. 4); Basel, Switzerland (Sept. 9-10); Boston, MA (Sept.16); and San Francisco, CA (Sept. 18).






Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Cancer Genetics: Key to Diagnosis, Therapy
When applied judiciously, cancer genetics directs caregivers to the right drug at the right time, while sparing patients of unnecessary or harmful treatments.
Study Reveals New Role for Hippo Pathway in Suppressing Cancer Immunity
Hippo pathway signaling regulates organ size by moderating cell growth, apoptosis and stem cell renewal, but dysregulation contributes to cancer development.
RNAi Activated in Response to Influenza
Discovery could lead to better ways of combating serious infections, including Ebola and Zika.
Gene Therapy Maintains Clotting Factor for Hemophilia Patients
Following a single gene therapy dose, the highest levels of an essential blood clotting factor IX were observed in hemophilia B patients.
Transporting Microscopic Cargo Between Human Cells
Scientists have developed a virus-inspired delivery system for material transport between cells.
Improving Drug Production with Computer Model
A model has been developed that can be used to improve and accelerate the production of biotherapeutics, cancer drugs, and vaccines.
Turning Off Asthma Attacks
Researchers discover a critical cellular “off” switch for the inflammatory immune response that causes asthma attacks.
New Strategy May Drop Cancer’s Guard
Scientists eye ways to deconstruct tumors’ protective wall with current diabetes drug.
Scientists Identify Unique Genomic Features in Testicular Cancer
The findings may shed light on factors in other cancers that influence their sensitivity to chemotherapy.
Smart Patch Releases Blood Thinners When Needed
Researchers have developed a smart patch that activelly monitors a patient's blood and releases blood thinning drugs when necessary.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!